Alzheimers/Dementia

Wednesday, November 19, 2025
1:00 pm EASTERN / 12:00 pm CENTRAL / 11:00 am MOUNTAIN / 10:00 am PACIFIC

Curious about the latest research and clinical uses of Methylene Blue? This upcoming program will explore its emerging role in treating conditions like Lyme disease, dementia, Alzheimer’s, post-COVID syndrome, and more—plus offer practical compounding tips for pharmacy teams.

Registration isn’t open yet, and this activity is not yet accredited—but if you want to be the first to get updates and know when registration goes live, sign up for notifications today!

This talk aims to illuminate the evolving landscape of Methylene Blue’s applications in healthcare, specifically focusing on its novelutilization for enhancing patient outcomes. Delving into recent advancements and promising research for specific conditions such as Lyme disease, dementia, bladder health, Alzheimer’s disease, post-COVID syndrome, and for anti-aging /nootropic effects.

The program will also cover Methylene Blue’s pharmacology, including mechanisms of action, pharmacokinetics, and pharmacodynamics, helping learners describe these key concepts in detail. In addition, participants will outline evidence-based prescribing protocols and dosing strategies for Methylene Blue in clinical practice. They will learn to recognize common adverse reactions and explain appropriate management strategies to ensure patient safety.

Pharmacists can expect to gain insights into how this versatile compound is contributing to improved patient care, paving theway for a more nuanced understanding of its potential impact on healthcare outcomes. Included with be practical compounding pharmacy process tips that will benefit Pharmacy Technicians and improve lab efficiency.